EUVIMEDEUVIMED entdecken
Crossref

pH‐Responsive β‐Glucans‐Complexed mRNA in LNPs as an Oral Vaccine for Enhancing Cancer Immunotherapy

Po-Kai Luo, Hui-Min Ho, Min-Chun Chiang, Li-An Chu, Ya-Han Chuang, Ping-Chiang Lyu, I-Chen Hu, Wan-An Chang, Sheng-Yao Peng, Jayachandran Jayakumar, Hsin-Lung Chen, Ming-Hsi Huang iD und 1 weitere

Advanced Materials · 2024-08 · 36 (33)

DOI: 10.1002/adma.202404830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 26.06.2024. Verfasst von Po-Kai Luo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, National Tsing Hua University, Hsinchu, 300044, Taiwan ROC. Hauptthemen laut MEDLINE: beta-Glucans, Immunotherapy, Cancer Vaccines, RNA, Messenger. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: National Science and Technology Council, National Health Research Institutes, Taiwan Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mRNA vaccines for cancer immunotherapy are commonly delivered using lipid nanoparticles (LNPs), which, when administered intravenously, may accumulate in the liver, potentially limiting their therapeutic efficacy. To overcome this challenge, the study introduces an oral mRNA vaccine formulation tailored for efficient uptake by immune cells in the gastrointestinal (GI) tract, known for its high concentration of immune cells, including dendritic cells (DCs). This formulation comprises mRNA complexed with β‐glucans (βGlus), a potential adjuvant for vaccines, encapsulated within LNPs (βGlus/mRNA@LNPs). The βGlus/mRNA complexes within the small compartments of LNPs demonstrate a distinctive ability to partially dissociate and reassociate, responding to pH changes, effectively shielding mRNA from degradation in the harsh GI environment. Upon oral administration to tumor‐bearing mice, βGlus/mRNA@LNPs are effectively taken up by intestinal DCs and local nonimmune cells, bypassing potential liver accumulation. This initiates antigen‐specific immune responses through successful mRNA translation, followed by drainage into the mesenteric lymph nodes to stimulate T cells and trigger specific adaptive immune responses, ultimately enhancing antitumor effects. Importantly, the vaccine demonstrates safety, with no significant inflammatory reactions observed. In conclusion, the potential of oral βGlus/mRNA@LNPs delivery presents a promising avenue in cancer immunotherapy, offering needle‐free and user‐friendly administration for widespread adoption and self‐administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-GlucansImmunotherapyCancer VaccinesRNA, MessengerNanoparticlesAnimalsAdministration, OralHydrogen-Ion ConcentrationMiceDendritic CellsLipidsmRNA VaccinesCell Line, TumorNeoplasmsMice, Inbred C57BLHumansLiposomes

Stichwörter der Autor:innen

cancer immunotherapylipid nanoparticlemRNA vaccineoral cancer vaccineβ‐glucans

Substanzen

beta-GlucansCancer VaccinesRNA, MessengerLipid NanoparticlesLipidsmRNA VaccinesLiposomes

Autor:innen und Institutionen

  • Department of Chemical Engineering, National Tsing Hua University, Hsinchu, 300044, Taiwan ROC.
  • National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, 350401, Taiwan ROC.
  • Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, 300044, Taiwan ROC.
  • Brain Research Center, National Tsing Hua University, Hsinchu, 300044, Taiwan ROC.
  • Institute of Bioinformatics and Structural Biology, National Tsing Hua University, Hsinchu, 300044, Taiwan ROC.

ORCID-Profile: Ming-Hsi Huang, Hsing-Wen Sung

Förderung

  • National Science and Technology Council
  • National Health Research Institutes
  • Taiwan Ministry of Education
  • Taiwan National Science and Technology Council
  • Academia Sinica Core Facility and Innovative Instrument Project

Zitieren

APA

Luo, P. K., Ho, H. M., Chiang, M. C., Chu, L. A., Chuang, Y. H., Lyu, P. C., Hu, I. C., Chang, W. A., Peng, S. Y., Jayakumar, J., Chen, H. L., Huang, M. H., & Sung, H. W. (2024). pH‐Responsive β‐Glucans‐Complexed mRNA in LNPs as an Oral Vaccine for Enhancing Cancer Immunotherapy. Advanced Materials, 36(33). https://doi.org/10.1002/adma.202404830

Vancouver

Luo PK, Ho HM, Chiang MC, Chu LA, Chuang YH, Lyu PC, et al. pH‐Responsive β‐Glucans‐Complexed mRNA in LNPs as an Oral Vaccine for Enhancing Cancer Immunotherapy. Advanced Materials. 2024;36(33). doi:10.1002/adma.202404830

BibTeX
@article{Luo2024,
  author = {Luo, Po-Kai and Ho, Hui-Min and Chiang, Min-Chun and Chu, Li-An and Chuang, Ya-Han and Lyu, Ping-Chiang and Hu, I-Chen and Chang, Wan-An and Peng, Sheng-Yao and Jayakumar, Jayachandran and Chen, Hsin-Lung and Huang, Ming-Hsi and Sung, Hsing-Wen},
  title = {pH‐Responsive β‐Glucans‐Complexed mRNA in LNPs as an Oral Vaccine for Enhancing Cancer Immunotherapy},
  journal = {Advanced Materials},
  year = {2024},
  volume = {36},
  number = {33},
  doi = {10.1002/adma.202404830}
}
Kostenlos starten →